Informationen:
Fehler:
ID
14955
Beschreibung
Open Label Extension Study of Conatumumab and AMG 479; ODM derived from: https://clinicaltrials.gov/show/NCT01327612
Link
https://clinicaltrials.gov/show/NCT01327612
Stichworte
Versionen (1)
- 09.05.16 09.05.16 -
Hochgeladen am
9. Mai 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Advanced Solid Tumors NCT01327612
Eligibility Advanced Solid Tumors NCT01327612
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Advanced Solid Tumors NCT01327612
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
conatumumab
Item
to be enrolled in this study, subjects must be currently enrolled in a prior amgen-sponsored conatumumab or amg 479 study and are eligible according to the parent study to receive their next dose of conatumumab (with or without co-therapy), or amg 479 alone.
boolean
C2346822 (UMLS CUI [1])
Eligibility
Item
subjects must have their eligibility assessed for this study and be enrolled within 30 days of their last treatment on the parent protocol
integer
C0013893 (UMLS CUI [1])
adverse event
Item
discontinued from a conatumumab study due to an adverse event considered by the investigator to be related to conatumumab treatment, including intolerance to conatumumab
boolean
C0877248 (UMLS CUI [1,1])
C2346822 (UMLS CUI [1,2])
C2346822 (UMLS CUI [1,2])
disease progression
Item
subjects determined to have disease progression during their participation in the parent amgen study
boolean
C0242656 (UMLS CUI [1])
contraceptive
Item
woman or man with partner of childbearing potential not consenting to use adequate contraceptive precautions ie, double barrier contraceptive methods (eg, diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last dose of protocol-specified therapy administration
boolean
C0700589 (UMLS CUI [1])
pregnant or breast feeding
Item
subject is pregnant or breast feeding, or planning to become pregnant within 6 months after the last dose of protocol-specified therapy administration
boolean
C0549206 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0006147 (UMLS CUI [1,2])
condom
Item
male subject with a pregnant partner who is not willing to use a condom during treatment and for an additional 6 months after the last dose of protocol-specified therapy administration
boolean
C3174747 (UMLS CUI [1])
subject has previously entered this study
Item
subject has previously entered this study
boolean
C2348568 (UMLS CUI [1])
study visits
Item
subject will not be available for protocol required study visits, to the best of the subject and investigator's knowledge
boolean
C0545082 (UMLS CUI [1,1])
C2603343 (UMLS CUI [1,2])
C2603343 (UMLS CUI [1,2])
Disorder
Item
subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures
boolean
C0012634 (UMLS CUI [1])
C1511481 (UMLS CUI [2])
C1511481 (UMLS CUI [2])